en · de · es · fr · pt
bpc-157-notes.peptides1004.com › Data › Background, Origin, And Naming — Quick Reference

Background, Origin, And Naming — Quick Reference

By Editorial Desk · published 2026-04-18 · last reviewed 2026-06-05 · Data

Mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-06-05 and is reviewed periodically as new material appears.

Background, Origin, and Naming

Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.

BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

BPC-157 Handling and Analysis

Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.

Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.

BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.

Bpc-157 at a glance

PropertyValueNotes
Molecular formulaC62H98N16O22Computed for the free peptide
Monoisotopic massApproximately 1419 DaReported values shift with counterion and hydration
Residue count15 amino acidsSequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
OriginFragment of human gastric juice proteinFirst described in early 1990s research reports
Common synonymsBPC 157; PL 14736; bepecinNaming varies across papers and catalogues

Background and Chemical Identity

BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.

The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.

Related pages on this site

Handling, Stability, and Analysis

Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.

Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.

Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.

Storage, Handling, and Analytical Verification

Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.

Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.

Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.

Background from the literature

==== Cardiotoxins / Cytotoxins ==== Cardiotoxins are components that are specifically toxic to the heart. They bind to particular sites on the surface of muscle cells and cause depolarisation → the toxin prevents muscle contraction. These toxins may cause the heart to beat irregularly or stop beating, causing death. An example is the three-fingered cardiotoxin III from Chinese cobra, an example of the short three-fingered family (InterPro: IPR003572). Snake example: mambas, and some Naja species

By October 18, 1985, the FDA approved the human growth hormone, developed almost entirely by Genentech, for sale in the United States, under the commercial name Protropin. In just two decades, Protropin sales exceeded $2 billion. Genentech had been able to manufacture, receive federal approval for, and market its own product, marking the successful execution of Swanson's plan to form out of Genentech a self sustainable biotech firm. Swanson left his position as CEO in 1990, taking on the position of chairman until his retirement from Genentech in 1996.

== Education == Fernandez received licentiate degrees in chemistry (1979) and mathematics (1980) from the Universidad Nacional del Sur, Argentina. He then earned a Ph.D. from Yale University in 1984 with a thesis entitled Structural Stability of Chemical Systems at Critical Regimes.

Cresskill is governed under the borough form of New Jersey municipal government, which is used in 218 municipalities (of the 564) statewide, making it the most common form of government in New Jersey. The governing body is comprised of the mayor and the borough council, with all positions elected at-large on a partisan basis as part of the November general election. A mayor is elected directly by the voters to a four-year term of office. The borough council includes six members elected to serve three-year terms on a staggered basis, with two seats coming up for election each year in a three-year cycle. The borough form of government used by Cresskill is a "weak mayor / strong council" government in which council members act as the legislative body with the mayor presiding at meetings and voting only in the event of a tie. The mayor can veto ordinances subject to an override by a two-thirds majority vote of the council. The mayor makes committee and liaison assignments for council members, and most appointments are made by the mayor with the advice and consent of the council. As of 2026, the mayor of the Borough of Cresskill is Republican John Morgan, who was appointed to serve a term of office ending on December 31, 2027. Members of the Cresskill Borough Council are Saverio Costa (R, 2028), Cheryl Furio (R, 2028), Arthur J. McLaughlin (D, 2026), Hector Olmo (R, 2026), Kathleen Savas (D, 2027), and Kathy M. Schultz-Rummel (R, 2027).

Sources: en.wikipedia.org

Reference notes

Trabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer. The most common adverse reactions include nausea, fatigue, vomiting, constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and headache. It is sold by Pharma Mar S.A. and Johnson and Johnson. It is approved for use in the European Union, Russia, South Korea and the United States. The European Commission and the U.S. Food and Drug Administration (FDA) granted orphan drug status to trabectedin for soft-tissue sarcomas and ovarian cancer. It was originally discovered in the sea squirt Ecteinascidia turbinata. Because natural yields are extremely low, its supply is based on a semisynthetic process starting from a chemical obtained from the bacterium Pseudomonas fluorescens.

=== AI skills shortage === The UK AI sector faces a critical and worsening skills shortage. The AI Labour Market Survey 2025, commissioned by DSIT and published in January 2026, found that 97% of surveyed organisations identified at least one gap in AI-related skills in the labour market, and that 57% reported a technical skills gap. The most significant gap identified was in understanding AI concepts and algorithms, with 28% of organisations reporting that technical skills shortages had directly impacted their ability to achieve business goals. Women account for only 20% of AI roles, a figure that has fallen by four percentage points since 2020, and 41% of firms do not employ people from minority ethnic backgrounds, exacerbating the talent pipeline constraint through underrepresentation.

Graduation from an accredited school with the appropriate degree Completion of supervised clinical experience or internship Passing a written examination and, in some states, an oral examination All U.S. state and Canadian province licensing boards are members of the Association of State and Provincial Psychology Boards (ASPPB), which created and maintains the Examination for Professional Practice in Psychology (EPPP). Many states require other examinations in addition to the EPPP, such as a jurisprudence (i.e. mental health law) examination and/or an oral examination. Most states also require a certain number of continuing education credits per year in order to renew a license, which can be obtained through various means, such as taking audited classes and attending approved workshops. Clinical psychologists require the psychologist license to practice, although other mental health provider licenses can be obtained with a master's degree, such as Marriage and Family Therapist (MFT), Licensed Professional Counselor (LPC), and Licensed Psychological Associate (LPA).

Sources: en.wikipedia.org

Reference notes

Growing evidence indicates that complete androgen receptor (AR) dysfunction disrupts systemic metabolic homeostasis and neither external nor endogenous estrogen can normalize it. AR absence is related to decrease in mature neutrophils in mice, but there is no evidence that human CAIS individuals have impaired neutrophil function. The proteome related to inflammation is predominantly inhibited in CAIS. Upregulation of IFN-β and IL-6 are reported in the blood of CAIS individuals. Leukocytes of CAIS individuals exhibit relative resistance to DNA damaging.

The simulated moving bed (SMB) technique is a variant of high performance liquid chromatography; it is used to separate particles and/or chemical compounds that would be difficult or impossible to resolve otherwise. This increased separation is brought about by a valve-and-column arrangement that is used to lengthen the stationary phase indefinitely. In the moving bed technique of preparative chromatography the feed entry and the analyte recovery are simultaneous and continuous, but because of practical difficulties with a continuously moving bed, simulated moving bed technique was proposed. In the simulated moving bed technique instead of moving the bed, the sample inlet and the analyte exit positions are moved continuously, giving the impression of a moving bed. True moving bed chromatography (TMBC) is only a theoretical concept. Its simulation, SMBC is achieved by the use of a multiplicity of columns in series and a complex valve arrangement. This valve arrangement provides for sample and solvent feed and analyte and waste takeoff at appropriate locations of any column, whereby it allows switching at regular intervals the sample entry in one direction, the solvent entry in the opposite direction, whilst changing the analyte and waste takeoff positions appropriately as well.

1 code 5' UTR 2 code activation peptide 2–4 code β-sandwich 4–12 code catalytic domain 12–13 code β-barrel 1 13–15 code β-barrel 2 B subunit gene is F13B. It is on chromosome 1 at the position 1q31–32.1. It spans 28 kbp, has 11 introns and 12 exons. Its mRNA is 2.2 kbp. Exon 1 codes 5' UTR. Exons 2–12 code the 10 different sushi domains.

The first true chromatography is usually attributed to the Russian-Italian botanist Mikhail Tsvet. Tsvet applied his observations with filter paper extraction to the new methods of column fractionation that had been developed in the 1890s for separating the components of petroleum. He used a liquid-adsorption column containing calcium carbonate to separate yellow, orange, and green plant pigments (what are known today as xanthophylls, carotenes, and chlorophylls, respectively). The method was described on December 30, 1901, at the 11th Congress of Naturalists and Doctors (XI съезд естествоиспытателей и врачей) in Saint Petersburg. The first printed description was in 1903, in the Proceedings of the Warsaw Society of Naturalists, section of biology. He first used the term chromatography in print in 1906 in his two papers about chlorophyll in the German botanical journal, Berichte der Deutschen Botanischen Gesellschaft. In 1907 he demonstrated his chromatograph for the German Botanical Society. Mikhail's surname "Цвет" means "color" in Russian, so there is the possibility that his naming the procedure chromatography (literally "color writing") was a way that he could make sure that he, a commoner in Tsarist Russia, could be immortalized. In a 1903 lecture (published in 1905), Tsvet also described using filter paper to approximate the properties of living plant fibers in his experiments on plant pigments—a precursor to paper chromatography.

Sources: en.wikipedia.org

Frequently asked questions

What is BPC-157?

BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.

Is BPC-157 approved for medical use?

No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.

Why is the literature on BPC-157 considered preliminary?

Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.

How is BPC-157 usually stored?

The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.

Network